Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This Week podcast, BioCentury editors discuss what the data mean, what the likely timelines are, and what the read throughs could be to other vaccines. They also discuss “China speed” and other takeaways from a survey of Chinese biopharmas conducted by BioCentury and BayHelix and discussions by panelists at the BioCentury-BayHelix seventh annual China Healthcare Summit.

Washington Editor Steve Usdin, who covered the data and its implications for Monday’s issue of BioCentury, argued that as Moderna Inc. (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) gear up to seek emergency use authorization for their respective vaccines, new data about temperature stability give Moderna’s mRNA-1273 vaccine a “huge advantage” over BNT162b2...